GW Pharmaceuticals awarded Queen’s Award for Enterprise in Innovation

GW Pharmaceuticals has received the Queen’s Award for Enterprise 2021 in the Innovation category, recognising the company’s work to harness cannabinoid science to create the world’s first regulatory approved, prescription cannabis-based medicines.

Since its inception in 1998, GW worked on the development, manufacture and commercialisation of regulatory approved cannabis-based medicines. Globally, GW has invested more than £1.3 billion in the research, development and infrastructure needed to bring medicines to patients.

Dr Geoffrey Guy, GW Founder and Chairman, said: “Much of what is known about the medical uses of cannabis was discovered by GW. We have led the way in understanding cannabinoid science and how, if harnessed correctly and taken through the regulatory approval pathway, it has the potential to improve the lives of patients and their families.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free